Review
Nanoparticles in clinical trials of COVID-19: An update

https://doi.org/10.1016/j.ijsu.2022.106818Get rights and content

Highlights

  • Development of economical, safe, and effective COVID-19 vaccines is need of the time.

  • Emergence of next generation NPs vaccines allow therapy through innovative therapeutic modalities.

  • NPs-based vaccines delivering SARS-CoV-2 antigens improves the effectiveness of COVID-19 vaccination regime.

  • NPs-based drug delivery systems increase drug bioavailability and reduces toxicity.

  • Production of efficient vaccines may be helpful in piling present arsenal of tools used to curtail COVID-19.

Abstract

Once the World Health Organization (WHO) declared the COVID-19 (Coronavirus Infectious Disease-19) outbreak to be pandemic, massive efforts have been launched by researchers around the globe to combat this emerging infectious disease. Strategies that must be investigated such as expanding testing capabilities, developing effective medicines, as well as developing safe and effective vaccines for COVID-19 disease that produce long-lasting immunity to human system. Now-a-days, bio-sensing, medication delivery, imaging, and antimicrobial treatment are just a few of the medical applications for nanoparticles (NPs). Since the early 1990s, nanoparticle drug delivery methods have been employed in clinical trials. Since then, the discipline of nanomedicine has evolved in tandem with expanding technological demands to better medicinal delivery. Newer generations of NPs have emerged in recent decades that are capable of performing additional delivery tasks, allowing for therapy via novel therapeutic modalities. Many of these next generation NPs and associated products have entered clinical trials and have been approved for diverse indications in the present clinical environment. For systemic applications, NPs or nanomedicine-based drug delivery systems have substantial benefits over their non-formulated and free drug counterparts. Nanoparticle systems, for example, are capable of delivering medicines and treating parts of the body that are inaccessible to existing delivery systems. As a result, NPs medication delivery is one of the most studied preclinical and clinical systems. NPs-based vaccines delivering SARS-CoV-2 antigens will play an increasingly important role in prolonging or improving COVID-19 vaccination outcomes. This review provides insights about employing NPs-based drug delivery systems for the treatment of COVID-19 to increase the bioavailability of current drugs, reducing their toxicity, and to increase their efficiency. This article also exhibits their capability and efficacy, and highlighting the future aspects and challenges on nanoparticle products in clinical trials of COVID-19.

Keywords

COVID-19
Nanoparticles
Pandemic
Vaccines
Drug delivery
Immunotherapy

Cited by (0)

View Abstract